title: Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma.
abstract: Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liver-directed therapy. Hepatic arterial concurrent chemoradiotherapy (CCRT) has been performed in our group, giving substantial local control but frequent failure. The aim of this study was to analyze patterns of failure and find out predictive clinical factors in HCC treated with a liver-directed therapy, CCRT. A retrospective analysis was done for 138 HCC patients treated with CCRT between May 2001 and November 2009. Protocol-based CCRT was performed with local radiotherapy (RT) and concurrent 5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (HAIC), followed by monthly HAIC (5-FU and cisplatin). Patterns of failure were categorized into three groups: infield, intrahepatic-outfield and extrahepatic failure. Treatment failure occurred in 34.0% of patients at 3 months after RT. Infield, intrahepatic-outfield and extrahepatic failure were observed in 12 (8.6%), 26 (18.7%) and 27 (19.6%) patients, respectively. Median progression-free survival for infield, outfield and extrahepatic failure was 22.4, 18 and 21.5 months, respectively. For infield failure, a history of pre-CCRT treatment was a significant factor (P = 0.020). Pre-CCRT levels of alpha-fetoprotein and prothrombin induced by vitamin K absence or antagonist-II were significant factors for extrahepatic failure (P = 0.029). Treatment failures after CCRT were frequent in HCC patients, and were more commonly intrahepatic-outfield and extrahepatic failures than infield failure. A history of pre-CCRT treatment and levels of pre-CCRT tumor markers were identified as risk factors that could predict treatment failure. More intensified treatment is required for patients presenting risk factors.
authors: Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea.
authors: Hyejung
authors: H
authors: Cha
authors: Hong In
authors: HI
authors: Yoon
authors: Ik Jae
authors: IJ
authors: Lee
authors: Woong Sub
authors: WS
authors: Koom
authors: Kwang-Hyub
authors: KH
authors: Han
authors: Jinsil
authors: J
authors: Seong
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality* / Q000628:therapy*; D059248:Chemoradiotherapy / Q000706:statistics & numerical data*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000517:prevention & control*; D012008:Recurrence; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
keywords: hepatic arterial concurrent chemoradiotherapy (CCRT); hepatocellular carcinoma; patterns of failure; risk factors
references: Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5
references: 12182985
references: Semin Liver Dis. 2010 Feb;30(1):61-74
references: 20175034
references: Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):393-7
references: 10030267
references: Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1331-5
references: 10889387
references: Histopathology. 2001 Feb;38(2):160-6
references: 11207829
references: J Gastroenterol Hepatol. 2007 Aug;22(8):1178-82
references: 17559361
references: World J Gastroenterol. 2003 Nov;9(11):2445-9
references: 14606073
references: Cancer. 2008 Sep 1;113(5):995-1003
references: 18615601
references: Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):386-90
references: 15313674
references: Am J Gastroenterol. 2008 Apr;103(4):914-21
references: 18177453
references: N Engl J Med. 2008 Jul 24;359(4):378-90
references: 18650514
references: Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):325-30
references: 9069303
references: Lancet Oncol. 2009 Jan;10(1):25-34
references: 19095497
references: Liver Int. 2005 Dec;25(6):1189-96
references: 16343071
references: Int J Cancer. 2004 Oct 20;112(1):44-50
references: 15305374
references: J Clin Oncol. 1993 Jul;11(7):1286-93
references: 8391066
references: J Clin Oncol. 2000 Jun;18(11):2210-8
references: 10829040
references: J Clin Oncol. 2005 Dec 1;23(34):8739-47
references: 16314634
references: Oncology. 2002;62 Suppl 1:57-63
references: 11868787
references: J Natl Cancer Inst. 2008 May 21;100(10):698-711
references: 18477802
references: Dig Dis Sci. 2010 Oct;55(10):2744-55
references: 20339916